
Michela Piezzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3223924/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors. International Journal of Molecular Sciences, 2020, 21, 6479.	4.1	71
2	Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients. International Journal of Molecular Sciences, 2017, 18, 459.	4.1	66
3	Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives. International Journal of Molecular Sciences, 2020, 21, 4579.	4.1	66
4	Targeting Autophagy in Breast Cancer. International Journal of Molecular Sciences, 2020, 21, 7836.	4.1	54
5	Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis. International Journal of Molecular Sciences, 2020, 21, 6400.	4.1	50
6	Multiple Effects of Ascorbic Acid against Chronic Diseases: Updated Evidence from Preclinical and Clinical Studies. Antioxidants, 2020, 9, 1182.	5.1	49
7	Inhibition of autophagy by chloroquine prevents resistance to PI3K/AKT inhibitors and potentiates their antitumor effect in combination with paclitaxel in triple negative breast cancer models. Journal of Translational Medicine, 2022, 20, .	4.4	25
8	The Use of Tocilizumab in Patients with COVID-19: A Systematic Review, Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Studies. Journal of Clinical Medicine, 2021, 10, 4935.	2.4	17
9	A Psychosocial Genomics Pilot Study in Oncology for Verifying Clinical, Inflammatory and Psychological Effects of Mind-Body Transformations-Therapy (MBT-T) in Breast Cancer Patients: Preliminary Results. Journal of Clinical Medicine, 2021, 10, 136.	2.4	12
10	Gene Expression Assay in the Management of Early Breast Cancer. Current Medicinal Chemistry, 2020, 27, 2826-2839.	2.4	7
11	Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center. Pharmaceutics, 2021, 13, 684.	4.5	5